They will assess BMI, weight-related conditions, medical history, and contraindications, then recommend which GLP-1 is best for your situation (Wegovy, Zepbound, or Foundayo)
Food and Drug Administration (FDA) has now approved two oral GLP-1 drugs: an oral version of Novo Nordisks Wegovy at the end of 2025, and Eli Lillys daily, non-peptide pillorforglipron, a distinct competitor to oral semaglutide and different from Eli Lillys injectable tirzepatidecalled Foundayo in April, which is notable because it can be taken without restrictions on timing or food or water intake
Symptoms include severe epigastric pain radiating to the back, nausea, vomiting, and elevated pancreatic enzymes
Metabolism was terminated by adding acetonitrile, and the samples were analyzed by HPLC/MS